MarketPulse
C

$COGT

5 articles found
4 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Cogent Biosciences, Inc.

Cogent Biosciences Showcases Dual Pipeline Advances at AACR 2026 Meeting

Cogent Biosciences highlights preclinical data for KRAS and HER2 inhibitors at AACR 2026, with IND submission planned for CGT1263.
COGTIND submissionAACR Annual Meeting
The Motley FoolThe Motley Fool··Jonathan Ponciano

RTW's $116M Cogent Bet Amplifies Biotech Rally Ahead of Key FDA Decision

RTW Investments purchases $116M stake in Cogent Biosciences, raising position to 2.7% of AUM amid 360% stock surge and anticipated 2026 FDA decision on lead drug.
COGTFDA approvalinstitutional investment
The Motley FoolThe Motley Fool··Jonathan Ponciano

Boone Capital Exits 372% Biotech Winner to Chase Emerging Clinical Plays

Boone Capital liquidates entire $13.57M Cogent Biosciences stake despite 372% gain, reallocating to earlier-stage biotech plays like TYRA. Strategic rebalancing in volatile sector.
MDTTYRAIONSCOGTBMRN+2biotechclinical-stage
BenzingaBenzinga··Vandana Singh

Cogent Biosciences Stock Surges on FDA Acceptance of Bezuclastinib Application

$COGT surges 5.24% after FDA accepts bezuclastinib NDA for Non-Advanced Systemic Mastocytosis, with decision expected by December 2026.
COGTFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Cogent Biosciences Presents Expanded SUMMIT Trial Results for Bezuclastinib at 2026 AAAAI Meeting

Cogent Biosciences presented expanded SUMMIT trial data showing bezuclastinib achieved significant symptom reduction and tryptase normalization in systemic mastocytosis patients, supporting its FDA regulatory applications.
COGTdisease modificationclinical results